STING Degrader-2
STING Degrader-2 is an orally active STING degrader that promotes proteasome-independent degradation of STING. STING Degrader-2 inhibits cGAMP-induced STING activation, suppresses STING oligomerization, and inhibits phosphorylation of STING and interferon regulatory factor 3 (IRF3). STING Degrader-2 reduces serum IFN-β and CXCL-10 levels in a cGAMP-induced autoimmune disease mouse model. STING Degrader-2 can be used for the research of autoimmune diseases.
For research use only. We do not sell to patients.
- Formula: C43H39FN4O8S
- Molecular Weight:790.86
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
STING Degrader-2 (compound SI-43) (6 h) inhibits cGAMP-induced STING activation in THP1-Blue ISG cells with an IC50 of 0.11 μM[1].
STING Degrader-2 (1 μM; 22 h after 2 h inhibitor pretreatment) induces degradation of STINGM155 in THP1 (STINGM155) cells via a proteasome-independent, lysosome-dependent pathway[1].
STING Degrader-2 (0.05-2.5 μM; 6 h) significantly reduces IFN-β and CXCL-10 secretion in THP1 cells and bone marrow-derived macrophages[1].
STING Degrader-2 (0.1-1 μM; 6-9 h) inhibits cGAMP-induced
phosphorylation of IRF3 and STING, as well as STING dimerization and oligomerization in THP1-Blue ISG cells[1].
STING Degrader-2 (0.01-10 μM; 6-48 h) induces degradation of mutants STINGS154 and STINGM155, while sparing STINGR232 and mSTING in THP1 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:THP1-Blue ISG cells
-
Concentration:0.1; 1 μM
-
Incubation Time:6; 9 h
-
Result:Decreased cGAMP-induced
phosphorylation of IRF3 and STING.
Induced STING dimerization and oligomerization.
-
Cell Line:THP1 cells; BMDM
-
Concentration:0.05; 0.5; 2.5 μM
-
Incubation Time:6 h
-
Result:Significantly reduced IFN-β and CXCL-10 secretion in THP1 cells and BMDM isolated from mice, at 0.05 and 0.5 μM.
-
Cell Line:THP1 cells harboring STINGS154, STINGM155, STINGR232, or mSTING
-
Concentration:0.01; 0.1; 0.5; 1; 5; 10 μM
-
Incubation Time:6; 12; 24; 48 h
-
Result:Induced degradation of mutants STINGS154 and STINGM155, while sparing STINGR232 and mSTING in THP1 cells.
Demonstrated low inhibition activity against STINGM155 in THP1 cells.
Parmacokinetics
| Species | Dose | Route | Cmax | T1/2 | AUC | CL/F |
|---|---|---|---|---|---|---|
| Mice[1] | 20 mg/kg | p.o. | 293 ng/mL | 3.3 h | 2022.7 ng·h/mL | 9762.0 mL/h/kg |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice with cGAMP-induced autoimmune disease[1]
-
Dosage:20 mg/kg (p.o.); 10 mg/kg (s.c.)
-
Administration:p.o. or s.c.; single dose
-
Result:Significantly reduced cGAMP-induced serum IFN-β levels.
Significantly reduced cGAMP-induced serum CXCL-10 levels.
Chemical Information
-
Molecular Weight 790.86
-
Formula C43H39FN4O8S
-
SMILES
O=C(NC1=CC(NS(=O)(C)=O)=C(O)C=C1)C2=CC=C(C3=CC4=C(C=C3)OC(C(C(C(N)=O)C5=C6C=C(OC)C=C5)N(C7=CC(F)=C(C(C)(C)C)C=C7)C6=O)=C4)C=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)